

Please indicate receipt of the below-identified paper:

<input type="checkbox"/> New Application For:		Priority Date:	
<input type="checkbox"/> Foreign priority already claimed			
<input type="checkbox"/> Continuation	<input type="checkbox"/> CIP	<input type="checkbox"/> Divisional	CPA <input type="checkbox"/>
<input type="checkbox"/> Specification:	Pages	<input type="checkbox"/> Drawings:	Sheets
<input type="checkbox"/> Response to Office Action Dated:		<input type="checkbox"/> Final Rejection	
<input checked="" type="checkbox"/> Other: IDS; Form PTO-1449; References (B1-B5, C1-C39); Transmittal letter; Postcard			
<input type="checkbox"/> Assignment Enclosed	<input checked="" type="checkbox"/> Cert. of Timely Mailing	<input type="checkbox"/> Exp. Mail:	

IDENTIFICATION OF APPLICATION

Serial No.: 09/636,179	
Title: ANGIOGENESIS TARGETING MOLECULES	
Applicant: Theresa Fauconnier <i>et al.</i>	Attorney: MBW
Client: Donahue Ernst & Young	F&J File No.: DEAY:003US
Mailed: October 24, 2001	Filed: Due Date:

BEST AVAILABLE COPY

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

MARK B. WILSON
PARTNER


INTERNET ADDRESS:
MBWILSON@FULBRIGHT.COM

DIRECT DIAL: 512/536-3035

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

October 24, 2001

FILE: DEAY:003US

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
October 24, 2001	
Date	Mark B. Wilson

Commissioner for Patents
Washington, DC 20231

RE: SN 09/636,179 "ANGIOGENESIS TARGETING MOLECULES" – Theresa Fauconnier
et al. (Client Reference: 2274-002948)


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (B1-B5, C1-C39).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10023537/MBW.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Mark B. Wilson
Reg. No. 37,259

MBW/cmb

Encl: as noted

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Theresa Fauconnier *et al.*

Serial No.: 09/636,179


Filed: August 10, 2000

For: ANGIOGENESIS TARGETING
MOLECULES

Group Art Unit: 1623

Examiner: Unknown

Atty. Dkt. No.: DEAY:003US/MBW

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
October 24, 2001	
Date	Mark B. Wilson

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10023537/MBW.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: October 24, 2001

Form PTO-1449 (modified)		Atty. Docket No. DEAY:003US/MBW	Serial No. 09/636,179
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Theresa Fauconnier <i>et al.</i>	
		Filing Date: August 10, 2000	Group: 1623
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	EP 0359347	3/21/90	Europe			
	B2	WO 94/11499	5/26/94	PCT			
	B3	WO 95/17419	6/29/95	PCT			
	B4	WO 96/06641	3/7/96	PCT			
	B5	WO 97/08313	3/6/97	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Arap <i>et al.</i> , "Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model," <i>Science</i> , 279:377-380, 1998.
	C2	Barinaga, "Peptide-guided cancer drugs show promise in mice," <i>Science</i> , 279:323-324, 1998.
	C3	Bollinger <i>et al.</i> , "Die Struktur von Ovalicin," <i>Helvetica Chimica Acta</i> , 56:819-830, 1973.
	C4	Borel and Stahelin, "Immunosuppressive effects of ovalicin-semicarbazone," <i>Agents and Actions</i> , 4/5:357-363, 1974.
	C5	Brown <i>et al.</i> , "Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract," <i>Cancer Res.</i> , 53:4727-4735, 1993.
	C6	Chen and Hawiger, "Reactivity of synthetic peptide analogs of adhesive proteins in regard to the interaction of human endothelial cells with extracellular matrix," <i>Blood</i> , 77:2200-2206, 1991.
	C7	Cheresh, "Death to a blood vessel, death to a tumor," <i>Nat. Medicine</i> , 4:395-414, 1998.

25085572.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. DEAY:003US/MBW	Serial No. 09/636,179
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Theresa Fauconnier <i>et al.</i>	
		Filing Date: August 10, 2000	Group: 1623
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C8	Dvorak <i>et al.</i> , "Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation," <i>Int. Arch. Allergy Immunol.</i> , 107:233-235, 1995.
	C9	Folkman and Klagsbrun, "Angiogenic factors," <i>Science</i> , 235:442-447, 1987.
	C10	Hanson and Eble, "An antiphage agent isolated from aspergillus sp," 527-529, 1946
	C11	Hayashi <i>et al.</i> , "GPIIb/IIIa integrin antagonists with the new conformational restriction unit, trisubstituted β -amino acid derivatives, and a substituted benzamidine structure," <i>J. Med. Chem.</i> , 41:2345-2360, 1998.
	C12	Houck <i>et al.</i> , "The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA," <i>Mol. Endo.</i> , 5(12):1806-1814, 1991.
	C13	Kireeva <i>et al.</i> , "Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin $\alpha_v\beta_3$," <i>J. Bio. Chem.</i> , 273(5):3090-3096, 1998.
	C14	Koivunen <i>et al.</i> , "Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins," <i>Bio/Technol.</i> , 13:265-270, 1995.
	C15	Kunicki <i>et al.</i> , "Molecular determinants of aRg-Gly-Asp Ligand Specificity for β_3 integrins," <i>J Bio. Chem.</i> , 272(7):4103-4107, 1997.
	C16	Kusaka <i>et al.</i> , "Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470), <i>Br. J. Cancer</i> , 69:212-216, 1994.
	C17	Liu <i>et al.</i> , "Labeling cyclic glycoprotein IIb/IIIa receptor antagonists with ^{99m}Tc by the preformed chelate approach: effects of chelators on properties of [^{99m}Tc]Chelator-peptide conjugates," <i>Bioconjugate Chem.</i> , 7:196-202, 1996.
	C18	Liu <i>et al.</i> , "Structure of human methionine aminopeptidase-2 complexed with fumagillin," <i>Science</i> , 282:1324-1327, 1998.
	C19	McDowell and Gadek, "Structural studies of potent constrained RGD peptides," <i>J. American Chem. Soc.</i> , 114(24):9245-9253, 1992.
	C20	McDowell <i>et al.</i> , "From peptide to non-peptide. 1. The elucidation of a bioactive conformation of the arginine-glycine-aspartic acid recognition sequence," <i>J. Am. Chem. Soc.</i> , 116:5069-5076, 1994.

25085572.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. DEAY:003US/MBW	Serial No. 09/636,179
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Theresa Fauconnier <i>et al.</i>	
		Filing Date: August 10, 2000	Group: 1623
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
-	C21	Meltzer <i>et al.</i> , "A technetium-99m SPECT imaging agent which targets the dopamine transporter in primate brain," <i>J. Medicinal Chem.</i> , 40(12):1835-1844, 1997.
-	C22	Mohri, "Interaction of fibronectin with integrin receptors: evidence by use of synthetic peptides," <i>Peptides</i> , 899-907, 1997.
-	C23	O'Neil <i>et al.</i> , "Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library," <i>Proteins: Structure, Function, and Genetics</i> , 14:509-515, 1992.
-	C24	Perrault <i>et al.</i> , "Relative importance of the glycoprotein Ib-binding domain and the RGD sequence of von Willebrand factor for its interaction with endothelial cells," <i>Blood</i> , 90:2335-2344, 1997.
-	C25	Piali <i>et al.</i> , "CD31/PECAM-1 is a ligand for $\alpha_v\beta_3$ integrin involved in adhesion of leukocytes to endothelium," <i>J. Cell Biol.</i> , 130:451-460, 1995.
-	C26	Plate <i>et al.</i> , "Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis," <i>Cancer Res.</i> , 53:5822-5827, 1993.
-	C27	Scarborough <i>et al.</i> , "Design of potent and specific integrin antagonists," <i>J. Bio. Chem.</i> , 286:1066-1073, 1993.
-	C28	Senger <i>et al.</i> , "A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines," <i>Cancer Res.</i> , 46:5629-5632, 1986.
-	C29	Sigg and Weber, "Isolierung und strukturaufklärung von Ovalicin," <i>Helvetica Chimica Acta</i> , 51:1395-1408, 1968.
-	C30	Sipkins <i>et al.</i> , "Detection of tumor angiogenesis in vivo by $\alpha_v\beta_3$ -targeted magnetic resonance imaging," <i>Nat. Medicine</i> , 4(5):623-626, 1998.
-	C31	Sun and Davies, "The cysteine-knot growth-factor superfamily," <i>Annu. Rev. Biophys. Biomol. Struct.</i> , 24:269-291, 1995.
-	C32	Takagi <i>et al.</i> , "Identification and characterization of vascular endothelial growth factor receptor," <i>Diabetes</i> , 45:1016-1023, 1996.
-	C33	Taunton, "How to starve a tumor," <i>Chem & Biol.</i> , 4:493-496, 1997.

25085572.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. DEAY:003US/MBW	Serial No. 09/636,179
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Theresa Fauconnier <i>et al.</i>	
		Filing Date: August 10, 2000	Group: 1623
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C34	Toi <i>et al.</i> , "Inhibition of vascular endothelial growth factor induced cell growth by an angiogenesis inhibitor AGM-1470 in capillary endothelial cells," <i>Oncology Reports</i> , 1:423-426, 1994.
	C35	Yamamoto <i>et al.</i> , "Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470)," <i>Anticancer Res.</i> , 14:1-4, 1994.
	C36	Yanai <i>et al.</i> , "Antitumor activity of a medium-chain triglyceride solution of the angiogenesis inhibitor TNP-470 (AGM-1470) when administered Via the hepatic artery to rats bearing walker 256 carcinosarcoma in the liver," <i>J. Pharm. And Experimental therapeutics</i> , 271(3):1267-1273, 1994.
	C37	Zhou <i>et al.</i> , "Identification and characterization of a fibroblast growth factor (FGF) binding domain in the cysteine-rich FGF receptor," <i>J. Bio. Chem.</i> , 272(8):5167-5174, 1997.
	C38	Zimmermann and Hartmann, "On the mode of action of the immunosuppressive sesquiterpene ovalicin," <i>Eur. J. Biochem.</i> , 118:143-150, 1981.
	C39	International Search Report dated January 7, 2000.

25085572.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.